New QMSR requirements changed the documentation expectations. Your procedures reference the old QSR. The gap analysis hasn't started, and you're prioritizing which updates will impact your next audit
Here's what's happening right now: Today alone, we tracked 26,202 new regulatory signals, including 26,000 new FDA Adverse Event Reports (MAUDE/MDRs) and 202 new Health Canada mdl entries. This volume underscores the critical need for robust post-market surveillance systems that align with updated QMSR and ISO 13485:2016 frameworks.
For RA Managers focused on audit preparedness and QMSR compliance, this data signals a heightened focus on documentation and risk management. The surge in adverse events suggests regulators are scrutinizing how effectively manufacturers integrate post-market data into their QMS. If your procedures still reference the old QSR, you're likely facing gaps in traceability and corrective action processes that could trigger findings during MDSAP audits or FDA inspections.
We analyzed this across 548,000+ regulatory records and found that timely updates to documentation correlate with fewer compliance issues in high-signal categories. Mapping these signals to your product portfolio can help prioritize gap analysis efforts.
See how your specific product codes compare and access tools for aligning with QMSR at truemeddevice.com
Related Regulatory Signals
[SHIRAKAWA OLYMPUS CO., LTD.] VISERA VIDEO SYSTEM CENTER — Malfunction
[TANDEM DIABETES CARE] T:SLIM X2 INSULIN PUMP WITH CONTROL-IQ TECHNOLOGY — Malfunction
[AESCULAP INC.] AESCULAP — Malfunction
BUR, ROUND
CEDARS-SINAI CARDIAC SUITE
SELF-CATH CLOSED SYSTEM PRE-LUBRICATED URINARY INTERMITTENT DRAINAGE CATHETER
See how these signals relate to your device
Start a free pilot to match signals to your product portfolio automatically.
Start PilotRelated Articles
Management review is next week. ISO 13485 5.6 requires external signal data as input. Your team hasn't gathered it yet, and you're staring at a blank slide for the board report on risk exposure and co
Here's what's happening right now: There were 10,384 new regulatory signals today, including 10,360 FDA Adverse Event Reports (MAUDE/MDRs) and 22 Health Canada mdl entries. Notably, Health Canada issued 2 new recalls: Auro-Canagliflozin for incorrect DIN labeling and LUXA-D for a foreign product in a capsule, both flagged for product safety. For your management review under QMSR and 21 CFR 820, this data isn't just noise—it's critical for quantifying risk exposure and benchmarking against compe
April 4, 2026
social_linkedinComplaint trends are rising for one product family but you can't tell if it's an industry-wide issue or yours alone. You're reviewing your CAPA dashboard, trying to prioritize investigations against l
Here's what's happening right now: 10,384 new regulatory signals hit the system today. That includes 10,360 new FDA adverse event reports (MAUDE/MDRs) and 2 new Health Canada recalls. One recall involves incorrect DIN labeling on a blister card (Auro-Canagliflozin), and another involves a foreign product in a capsule batch (LUXA-D). For your CAPA prioritization and complaint handling, notice the pattern in the MDRs: multiple reports for infusion set tubing detachment events and software/app mal
April 4, 2026
social_linkedinA competitor's device just got recalled. Your auditor will ask: 'How did you evaluate whether this affects your products?' You're reviewing the alert, knowing it could trigger a supplier audit or requ
Here's what's happening right now: 2 new Health Canada recalls were issued this week, both for product safety issues. Auro-Canagliflozin has affected lots with incorrect DIN labeling on blister cards, and LUXA-D has a capsule containing a foreign product in the batch. This adds to 10,360 new FDA Adverse Event Reports (MAUDE/MDRs) and 22 new Health Canada mdl signals today, totaling 10,384 new regulatory signals. For RA Managers focused on audit preparedness and post-market surveillance, these s
April 4, 2026